866-997-4948(US-Canada Toll Free)

Mirapex ER Analysis and Estimates from 2009 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 34 Pages


GlobalDatas pharmaceuticals report, Mirapex ER Analysis and Estimates from 2009 to 2020 provides Mirapex ERsales estimates for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2009-2020). The report also includes information on Parkinson's Disease market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope
  • Therapy area profile including patient population for the Japan (seven major markets)
  • Analysis and review of Mirapex ER including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Mirapex ER including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2009-2020 for Mirapex ER in the US and EU5
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Parkinsons Disease 4
2.2 Symptoms of Parkinsons Disease 4
2.3 Diagnosis of Parkinsons disease 5
2.4 Parkinsons Disease Treatment Strategies 5
2.5 Parkinsons Disease Market 6
2.6 Epidemiology 6
2.7 Parkinsons Disease by Age and Gender 6
2.8 Etiology 7
2.9 GlobalData Report Guidance 7

3 Parkinsons Disease: Market Characterization 8
3.1 Parkinsons Disease Market 8
3.2 Parkinsons Disease Market Forecasts and CAGR 8
3.3 Factors Affecting Parkinsons Disease Market 9
3.3.1 High Prevalence: PD is the Second Most Frequent Neurodegenerative Disorder 9
3.3.2 Increase in Old Age Population 9
3.3.3 Patent Expiry of Prominent Drugs 9

4 Stages of Parkinsons Disease and Comparison of Treatments 10
4.1 The Hoehn and Yahr Scale 10
4.2 Modified Hoehn and Yahr Scale 10
4.3 The UPDRS 11

5 Staging of Parkinsons Disease 14
5.1 Distribution of Parkinsons disease Patients by Age Groups 14
5.2 Distribution of Patients by Stages 14

6 Mirapex ER 15
6.1 Introduction 15
6.2 Mechanism of Action 15
6.3 Clinical Studies 15
6.3.1 Studies in Patients with Early Parkinsons Disease 15
6.3.2 Studies in Patients with Advanced Parkinson's Disease 15
6.3.3 Studies in Patients Who Made a Switch Over From Mirapex To Mirapex ER 16
6.4 Approval History of Mirapex ER 17
6.5 Factors Affecting Sales of Mirapex ER 17
6.5.1 Used in Multiple Regimens 17
6.5.2 Dosing Convenience 17
6.5.3 Generic Competition from Mirapex IR 17
6.5.4 Short Product Life Cycle 17
6.5.5 Absence in Japan 17
6.5.6 Behavioral Addictions 18
6.6 Drug Evaluation 18
6.6.1 Drug Risk Benefit Score 18
6.6.2 Intensity of Competition 19
6.7 Sales Estimates 19
6.7.1 Target Patient Pool for Mirapex ER 19
6.7.2 Dosing 20
6.7.3 Market Penetration 21
6.7.4 Annual Cost of Therapy 21
6.7.5 Sales Estimates of Mirapex ER 22

7 Parkinson Disease Market: Appendix 30
7.1 Market Definitions 30
7.2 List of Abberiviations 30
7.3 Research Methodology 30
7.3.1 Coverage 30
7.3.2 Secondary Research 30
7.3.3 Forecasting 31
7.3.4 Number of Patients Approved to take the Drug 31
7.3.5 Net Penetration of Drug 31
7.3.6 Net Annual Dosing 32
7.3.7 Annual Cost of Therapy 32
7.3.8 Primary Research 32
7.3.9 Expert Panels 33
7.4 Drug Sales Estimates Model 33
7.5 Contact Us 33
7.6 Disclaimer 33
7.7 Sources 34

List of Table


Table 1: Clinical Motor and Nonmotor Features of Parkinsons Disease 4
Table 2: Hoehn and Yahr Stages of Parkinsons Disease 10
Table 3: Hoehn and Yahr Stages of Parkinsons Disease 10
Table 4: Four Items, Part 1 of UPDRS 11
Table 5: Thirteen Items, Part 2 of Parkinsons disease 11
Table 6: Fourteen Items, Part 3 of UPDRS 12
Table 7: Fourteen Items, Part 3 of UPDRS 12
Table 8: Distribution of Parkinsons patients according to Hoehn and Yahr Classification 14
Table 9: Primary End Point Analysis (UPDRS II+III) 16
Table 10: Secondary End Point Analysis (Percentage Off Time) 16
Table 11: Approval History of Mirapex ER 17
Table 12: Drug Risk Benefit Score of Mirapex ER 18
Table 13: Dosing Schedule of Mirapex ER for Parkinsons Disease 20
Table 14: Annual Cost of Therapy, 2010 21
Table 15: Mirapex ER, Parkinsons Disease, Global, Sales Estimates ($m), 20092020 22
Table 16: Mirapex ER, Parkinsons Disease, The US, Sales Estimates ($m), 20102020 23
Table 17: Mirapex ER, Parkinsons Disease, The UK, Sales Estimates ($m), 20092020 24
Table 18: Mirapex ER, Parkinsons Disease, France, Sales Estimates ($m), 20092020 25
Table 19: Mirapex ER, Parkinsons Disease, Germany, Sales Estimates ($m), 20092020 26
Table 20: Mirapex ER, Parkinsons Disease, Italy, Sales Estimates ($m), 20092020 27
Table 21: Mirapex ER, Parkinsons Disease, Spain, Sales Estimates ($m), 20092020 28

List of Chart


Figure 1: Current Pharmacologic Therapies for Parkinsons disease and Their Potential Sites of Action in the CNS 5
Figure 2: The Age-Specific Prevalence Rates of Parkinsons Disease in the Elderly Among Five European Countries, 2003 6
Figure 3: Parkinsons Disease, Global, Market Size Estimates ($bn), 20102020 8
Figure 4: Proportion of Population 60 Years or Older, World, 1950-2050 9
Figure 5: Points Distribution of UPDRS 13
Figure 6: Distribution of Parkinsons patients by Hoehn & Yahr Classification 14
Figure 7: Drug Model Diagram of Mirapex ER in the US and EU 20
Figure 8: Mirapex ER, Parkinsons Disease, Global, Sales Estimates ($m), 20092020 22
Figure 9: Mirapex ER, Parkinsons Disease, The US, Sales Estimates ($m), 20102020 23
Figure 10: Mirapex ER, Parkinsons Disease, The UK, Sales Estimates ($m), 20092020 24
Figure 11: Mirapex ER, Parkinsons Disease, France, Sales Estimates ($m), 20092020 25
Figure 12: Mirapex ER, Parkinsons Disease, Germany, Sales Estimates ($m), 20092020 26
Figure 13: Mirapex ER, Parkinsons Disease, Italy, Sales Estimates ($m), 20092020 27
Figure 14: Mirapex ER, Parkinsons Disease, Spain, Sales Estimates ($m), 20092020 28
Figure 15: Mirapex ER, Parkinsons Disease, Global, Sales Distribution by Country (%), 2012 29
Figure 16: Drug Model Diagram 32
Figure 17: Patients Approved for the Drug 32

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *